Pharma Q3 Earnings Preview - Elevated Price Erosion Could Impact Business In U.S.: Axis Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Axis Securities Report
We expect, pharma universe could report high single digit growth (4.0% YoY), majorly driven by injectables and generic segment. India pharma market grew by 5.8% that is driven by a volume bounce back and recovery in sales of non Covid-19 products.
In U.S., generic market continues to be challenging, with mid-single-digit to low-double-digit price erosion across companies, owing to excess supplies in the market and limited one-time/off-contract sales currently.
In overall, earnings for the pharma universe would moderate and come in flat YoY, after six quarters of healthy performance. Increased competitive pressure on the U.S. base business – coupled with the reduced pace of launches and lower Covid-related off-take – is expected to drag down the overall sector performance in Q3 FY22.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.